Review
Immunology
Liangliang Zhou, Haiyuan Shen, Xiaofeng Li, Hua Wang
Summary: This review discusses the role of innate immune cells and their endoplasmic reticulum stress in the occurrence of NAFLD and the progression of cirrhosis. Complex immune responses and ER stress play a critical role in triggering and amplifying hepatic inflammation and fibrosis, revealing the underlying mechanisms of NAFLD/NASH.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, Research & Experimental
Poliana C. Marinello, Paola S. Cella, Mayra T. J. Testa, Phillipe B. Guirro, Walison Augusto da Silva Brito, Camila S. Padilha, Alessandra L. Cecchini, Robin P. da Silva, Jose Alberto R. Duarte, Rafael Deminice
Summary: This study investigated the effects of creatine supplementation on the pathogenesis of non-alcoholic fatty liver disease and alcoholic liver disease. The results showed that creatine supplementation prevented high-fat diet-induced non-alcoholic fatty liver disease but exacerbated ethanol-induced alcoholic liver disease. The exacerbating effects may be related to oxidative stress and inflammation-mediated upregulation of ethanol metabolism.
Article
Medicine, Research & Experimental
Yvelise Ferro, Roberta Pujia, Elisa Mazza, Lidia Lascala, Oscar Lodari, Samantha Maurotti, Arturo Pujia, Tiziana Montalcini
Summary: This study evaluated the effects of a novel combination of nutraceuticals in treating fatty liver disease in adults, and showed that the nutraceutical was both safe and effective in reducing liver fat content over a 12-week period.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Review
Cell Biology
Amila Iriskic Atic, Maja Thiele, Alexander Munk, Louise Torp Dalgaard
Summary: MicroRNAs (miRNAs) secreted by the liver have the potential to be important biomarkers for nonalcoholic liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Several miRNAs, including miR-122, miR-21, miR-34a, miR-192, miR-193, and the miR-17-92 miRNA-cluster, are consistently associated with NAFLD/NASH. These miRNAs show potential as diagnostic markers for NAFLD/NASH, although more research is needed to understand their specificity and regulation.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
(2023)
Review
Pharmacology & Pharmacy
Siyu Yu, Chunlin Li, Guang Ji, Li Zhang
Summary: Excessive intake of fructose, especially industrial fructose, has been linked to the development of NAFLD by affecting endogenous fructose production, gut barrier, microbiota community, leading to lipid accumulation in the liver and inflammation. Targeting the absorption and metabolism of fructose may be a promising strategy for NAFLD treatment.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Lauren A. Newman, Zivile Useckaite, Jillian Johnson, Michael J. Sorich, Ashley M. Hopkins, Andrew Rowland
Summary: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease. Diagnosis of the progressive form, non-alcoholic steatohepatitis (NASH), requires invasive liver biopsy. This study demonstrates that the selective isolation of circulating extracellular vesicles originating from hepatocytes can improve the performance of miRNA biomarkers, allowing for reliable distinction between NAFL and NASH patients.
Article
Gastroenterology & Hepatology
Caizhi Liu, Bing Zhou, Meiyao Meng, Wenjun Zhao, Dongmei Wang, Youwen Yuan, Ying Zheng, Jin Qiu, Yu Li, Guoqiang Li, Xuelian Xiong, Hua Bian, Huijie Zhang, Hua Wang, Xinran Ma, Cheng Hu, Lingyan Xu, Yan Lu
Summary: The study identified FOXA3 as a key bridging molecule connecting ER stress and NAFLD progression, with its deficiency alleviating fatty liver. Increased levels of FOXA3 were found in the livers of obese mice and patients with NAFLD, suggesting FOXA3 as a potential therapeutic target for fatty liver disease.
JOURNAL OF HEPATOLOGY
(2021)
Article
Biology
Kyungchul Song, Hae Won Lee, Han Saem Choi, Goeun Park, Hye Sun Lee, Su Jin Kim, Myeongseob Lee, Junghwan Suh, Ahreum Kwon, Ho-Seong Kim
Summary: This study investigated various markers for assessing NAFLD in youths and found that modified TyG indices, APRI-BMI SDS, and HSI are strongly associated with NAFLD. These markers may be useful for identifying youths who require treatment.
Review
Nutrition & Dietetics
Maitane Gonzalez-Arceo, Saioa Gomez-Zorita, Leixuri Aguirre, Maria P. Portillo
Summary: An overview of scientific evidence on the beneficial effects of microalgae and macroalgae extracts on non-alcoholic fatty liver disease (NAFLD) shows improvement in the condition. Further research is needed to understand the mechanisms of action and confirm the effects observed in rodents in human studies.
Review
Biochemistry & Molecular Biology
Abdulrahman Ismaiel, Oana Sabina Ciobanu, Mohamed Ismaiel, Daniel-Corneliu Leucuta, Stefan-Lucian Popa, Liliana David, Dilara Ensar, Nahlah Al Srouji, Dan L. Dumitrascu
Summary: The study evaluated the AIP as a non-invasive modality for predicting NAFLD, showing a comparable predictive effect in males and females, but no significant difference between NAFLD patients and controls in AIP values. The AIP is considered a reliable biomarker for diagnosing NAFLD.
Article
Multidisciplinary Sciences
Juan Macias, Pablo Parra-Membrives, Francisco Sosa-Moreno, Pilar Rincon, Dario Martinez-Baena, Marta Fernandez-Fuertes, Jose M. Lorente-Herce, Rafael C. Martinez, Granada Jimenez-Riera, Anais Corma-Gomez, Alejandro Gonzalez-Serna, Juan A. Pineda, Luis Miguel Real
Summary: The diagnosis of non-alcoholic steatohepatitis (NASH) requires liver biopsy, but we have developed a predictive model based on routine clinical and transient hepatic elastography data to diagnose NASH. One index in the model, called CAP-insulin resistance (CIR) score, can reliably identify patients with and without NASH.
SCIENTIFIC REPORTS
(2022)
Review
Biotechnology & Applied Microbiology
Margalida Monserrat-Mesquida, Cristina Bouzas, Catalina M. Mascaro, Silvia Tejada, Antoni Sureda
Summary: Background: NAFLD is a common liver disease with increasing prevalence, and there is currently no clear management strategy or specific pharmacological treatment available. This review summarizes the potential therapeutic effects of probiotics in NAFLD, based on studies conducted in animal models and clinical trials. The results demonstrate that probiotic supplementation can reduce liver steatosis, normalize lipid profiles and liver enzyme activities, decrease lipogenesis, increase lipolysis, alleviate oxidative and inflammatory states, and normalize intestinal dysbiosis. Clinical trials have also shown improvements in serum transaminases, lipid profiles, and inflammatory markers. Therefore, probiotic supplementation can be considered as a potential therapy for managing NAFLD.
FERMENTATION-BASEL
(2023)
Article
Medicine, General & Internal
Marco Castellana, Rossella Donghia, Vito Guerra, Filippo Procino, Luisa Lampignano, Fabio Castellana, Roberta Zupo, Rodolfo Sardone, Giovanni De Pergola, Francesco Romanelli, Pierpaolo Trimboli, Gianluigi Giannelli
Summary: The fatty liver index (FLI) has been shown to perform well in stratifying the risk of non-alcoholic fatty liver disease (NAFLD) but has weak evidence in excluding or diagnosing the disorder. Studies found similar performance in using ultrasound versus other imaging modalities.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Immunology
Yamei Duan, Xiongfeng Pan, Jiayou Luo, Xiang Xiao, Jingya Li, Prince L. Bestman, Miyang Luo
Summary: This study found a significant association between inflammatory cytokines and non-alcoholic fatty liver disease (NAFLD). Increased concentrations of C-reactive protein (CRP), interleukin-1 beta (IL-1 beta), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and intercellular adhesion molecule-1 (ICAM-1) were significantly associated with increased risks of NAFLD.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Tieshan Teng, Shuai Qiu, Yiming Zhao, Siyuan Zhao, Dequan Sun, Lingzhu Hou, Yihang Li, Ke Zhou, Xixi Yu, Changyong Yang, Yanzhang Li
Summary: Non-alcoholic fatty liver disease (NAFLD) is strongly correlated with obesity, insulin resistance, metabolic syndrome, and genetic components. The disease progression includes non-alcoholic fatty liver, non-alcoholic steatohepatitis, and liver cirrhosis, with different clinical phenotypes. There is currently no FDA-approved medication specifically for treating NAFLD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
